Newtown based manufacturer, CellPath, specialises in the manufacture and supply of equipment and services used in cancer diagnostics.
The Welsh company, which is part of the wider US based StatLab Medical Products group, has contacts in more than 170 countries across Europe, America, Asia, Africa and the Middle East, including the UAE, Qatar and Iraq.
Over the last five years, the company has placed a drive on international sales and has seen its exports and number of worldwide distributors double during that time.
Export Ambitions
Over the last 24 months, the company has doubled its export turnover in the Middle East and South Asia, with CellPath having entered Saudi Arabia for the first time. The regions have been key target markets thanks to their rapidly growing medical sectors, following government investments in healthcare and increasing levels of medical tourism.
With CellPath now being part of the StatLab group of companies, there are even more opportunities for existing distribution clients to access the portfolios of products from other group businesses.
An international focus
CellPath has boasted an international outlook since it was first established in 1990, when it secured some of its first overseas clients after attending the world’s biggest medical trade show held in Dusseldorf.
Trade shows have remained a key part of its export strategy ever since and will support its ongoing expansion plans. The company has attended numerous exhibitions around the world as part of Welsh Government trade missions, enabling it to explore trade opportunities in different regions, meet with potential new distribution partners and strengthen its relationships with existing clients also attending.
Investment in Wales
Following increased demand for its products overseas, over the last two years, CellPath has invested over £2m in a new international distribution warehouse and machinery at its Welsh headquarters.
The company has also opened a new office at the base and is looking to increase its sales team in order to support its expansion.
CellPath’s export success has been assisted by the Welsh Government which has helped it to attend trade missions and visit new regions as well as conduct research into target markets to determine the appetite for its products.
Mark Wallace, International Sales Manager at CellPath, said: “It is a very exciting time for CellPath as we further develop and merge with our parent company, StatLab.
“With the existing success of export sales at CellPath and the experience of the team here, the company has been selected as the export hub for all group products, acting as the anchor for export sales across all companies. Being a part of StatLab will offer a great boost to CellPath with many opportunities for export growth ahead.
“We have been extremely lucky to receive a range of of support from the Welsh Government over the years including help researching target markets and identifying potential new partners, as well assistance to attend trade missions and global events. Notably, we have had support to join the upcoming Medlab Asia trade show and we’re also hoping to attend the next Medica event as members of the delegation from Wales.”